HomeCompareOBCI vs ABBV

OBCI vs ABBV: Dividend Comparison 2026

OBCI yields 4.80% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OBCI wins by $4905.00M in total portfolio value
10 years
OBCI
OBCI
● Live price
4.80%
Share price
$13.03
Annual div
$0.63
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4905.10M
Annual income
$4,716,447,961.03
Full OBCI calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — OBCI vs ABBV

📍 OBCI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOBCIABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OBCI + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OBCI pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OBCI
Annual income on $10K today (after 15% tax)
$408.23/yr
After 10yr DRIP, annual income (after tax)
$4,008,980,766.88/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, OBCI beats the other by $4,008,959,710.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OBCI + ABBV for your $10,000?

OBCI: 50%ABBV: 50%
100% ABBV50/50100% OBCI
Portfolio after 10yr
$2452.60M
Annual income
$2,358,236,366.39/yr
Blended yield
96.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

OBCI
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OBCI buys
0
ABBV buys
0
No recent congressional trades found for OBCI or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOBCIABBV
Forward yield4.80%3.06%
Annual dividend / share$0.63$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$4905.10M$102.3K
Annual income after 10y$4,716,447,961.03$24,771.77
Total dividends collected$4891.82M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OBCI vs ABBV ($10,000, DRIP)

YearOBCI PortfolioOBCI Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,661$960.55$11,550$430.00+$111.00OBCI
2$14,570$2,093.57$13,472$627.96+$1.1KOBCI
3$20,480$4,889.72$15,906$926.08+$4.6KOBCI
4$34,760$12,846.64$19,071$1,382.55+$15.7KOBCI
5$77,949$40,755.74$23,302$2,095.81+$54.6KOBCI
6$254,236$170,829.91$29,150$3,237.93+$225.1KOBCI
7$1,313,473$1,041,441.16$37,536$5,121.41+$1.28MOBCI
8$11,462,357$10,056,940.58$50,079$8,338.38+$11.41MOBCI
9$176,310,406$164,045,684.48$69,753$14,065.80+$176.24MOBCI
10$4,905,100,096$4,716,447,961.03$102,337$24,771.77+$4905.00MOBCI

OBCI vs ABBV: Complete Analysis 2026

OBCIStock

Ocean Bio-Chem, Inc. manufactures, markets, and distributes appearance, performance, and maintenance products for the marine, automotive, power sports, recreational vehicle, home care, and outdoor power equipment markets in the United States and Canada. The company offers marine products, including polishes, cleaners, protectants, waxes, enzyme fuel treatments, private label products, motor and teak oils, boat washes, vinyl and teak cleaners, bilge and hull cleaners, silicone and polyurethane sealants, polysulfide sealants, gasket materials, lubricants, antifouling additives, and anti-freeze coolants; and brushes, brush handles, tie-downs, and other related accessories. It also manufactures automotive products, such as fuel treatments for gas and diesel engines, motor oils, greases, and related items; anti-freeze and windshield washes; and automotive polishes, cleaners, and other items. In addition, the company offers fuel treatment and other specialty products to the recreational vehicle market; solutions to various problems associated with E-10 fuel; and other specialty recreational vehicle/power sports products, including cleaners, polishes, detergents, fabric cleaners and protectors, silicone sealants, waterproofers, gasket materials, degreasers, vinyl cleaners and protectors, toilet treatment fluids, and anti-freeze/coolants. Further, it provides solutions to rectify operating engine problems in commercial lawn, and other home and garden power equipment; deodorizers, disinfectants, and sanitizers, as well as mildew odor control bags and boat odor sanitizers; blends and packages chemical formulations; and manufactures PVC and HDPE blow molded bottles. The company sells its products under the Star Tron, Performacide, and Star brite brands through retailers and online retailers, as well as to distributors. Ocean Bio-Chem, Inc. was founded in 1973 and is headquartered in Fort Lauderdale, Florida. As of August 9, 2022, Ocean Bio-Chem, Inc. operates as a subsidiary of OneWater Marine Inc.

Full OBCI Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this OBCI vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OBCI vs SCHDOBCI vs JEPIOBCI vs OOBCI vs KOOBCI vs MAINOBCI vs JNJOBCI vs MRKOBCI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.